From the other side of the coin.......looking at users rather than receivers of CC.
2014 and 2015 has seen the number of users of the product increase from 8 (all from 3 centres in australia) to now 60 centres from 5 extra geographical regions accross the globe.
Each procedure using CC has been performed by a specialist with a swagger of registrars (trainee CT surgeons) at anywhere in their 5 ish years of specialty training watching and learning.
Fast forward 5 years and these trainees will most likely be qualified cardio thoracic surgeons with CC as the only bio scaffold material that they know of.
As most of us believe, the product speaks for it self but, when the future end users know no other alternative, it is almost better than free advertising!
The current cash burn with staff costs may be seen as excessive from certain points of view, but the long term effect of the market penetration could very well be worth it.
- Forums
- ASX - By Stock
- AVR
- Ann: Admedus expands CardioCel market
Ann: Admedus expands CardioCel market, page-79
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M |
Open | High | Low | Value | Volume |
$18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 109 | $18.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.10 | 700 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 48 | 17.750 |
1 | 26 | 17.650 |
1 | 200 | 17.560 |
1 | 500 | 17.550 |
1 | 1 | 17.510 |
Price($) | Vol. | No. |
---|---|---|
18.100 | 700 | 1 |
18.300 | 150 | 1 |
18.500 | 43 | 1 |
18.690 | 550 | 1 |
18.750 | 143 | 1 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
AVR (ASX) Chart |